Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage.


Journal

Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179

Informations de publication

Date de publication:
24 06 2021
Historique:
received: 28 03 2020
accepted: 03 06 2021
entrez: 25 6 2021
pubmed: 26 6 2021
medline: 17 8 2021
Statut: epublish

Résumé

Quantitation of androgen receptor variant (AR-V) expression in circulating tumor cells (CTCs) from patients with metastatic castration-resistant prostate cancer (mCRPC) has great potential for treatment customization. However, the absence of a uniform CTC isolation platform and consensus on an analytical assay has prevented the incorporation of these measurements in routine clinical practice. Here, we present a single-CTC sensitive digital droplet PCR (ddPCR) assay for the quantitation of the two most common AR-Vs, AR-V7, and AR-v567es, using antigen agnostic CTC enrichment. In a cohort of 29 mCRPC patients, we identify AR-V7 in 66% and AR-v567es in 52% of patients. These results are corroborated using another gene expression platform (NanoString

Identifiants

pubmed: 34168263
doi: 10.1038/s42003-021-02321-9
pii: 10.1038/s42003-021-02321-9
pmc: PMC8225618
doi:

Substances chimiques

AR protein, human 0
Receptors, Androgen 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

785

Subventions

Organisme : NCI NIH HHS
ID : R01 CA179100
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA216800
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA062948
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA203702
Pays : United States

Références

J Urol. 2016 Dec;196(6):1758-1763
pubmed: 27449259
Clin Cancer Res. 2017 Feb 1;23(3):726-734
pubmed: 27489290
JCO Precis Oncol. 2017;2017:
pubmed: 29170762
Clin Cancer Res. 2019 Mar 15;25(6):1880-1888
pubmed: 30301829
Int J Oncol. 2005 Jul;27(1):49-57
pubmed: 15942643
Clin Cancer Res. 2017 Nov 15;23(22):6802-6811
pubmed: 28842510
Cancer Res. 2014 Apr 15;74(8):2270-2282
pubmed: 24556717
Science. 2015 Sep 18;349(6254):1351-6
pubmed: 26383955
J Neurovirol. 2014 Aug;20(4):341-51
pubmed: 24781526
Eur Urol. 2019 Jan;75(1):88-99
pubmed: 29673712
Clin Cancer Res. 2008 Oct 1;14(19):6302-9
pubmed: 18829513
Cell. 2015 May 21;161(5):1215-1228
pubmed: 26000489
Cancers (Basel). 2019 Jul 13;11(7):
pubmed: 31337040
Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17492-7
pubmed: 24101480
Anal Chem. 2012 Jan 17;84(2):1003-11
pubmed: 22122760
J Clin Invest. 2019 Jan 2;129(1):192-208
pubmed: 30334814
J Clin Oncol. 2019 May 1;37(13):1120-1129
pubmed: 30865549
Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9236-41
pubmed: 10430926
Nat Clin Pract Urol. 2009 Feb;6(2):76-85
pubmed: 19198621
Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436
pubmed: 31061129
Clin Chem. 2013 Jun;59(6):892-902
pubmed: 23570709
JAMA Oncol. 2016 Nov 1;2(11):1441-1449
pubmed: 27262168
PLoS One. 2013 Sep 20;8(9):e75296
pubmed: 24073259
PLoS One. 2011 Apr 28;6(4):e19059
pubmed: 21552559
Nat Commun. 2018 Jun 19;9(1):2404
pubmed: 29921838
Cells. 2019 Jul 08;8(7):
pubmed: 31288377
Cytotherapy. 2005;7(2):171-85
pubmed: 16040397
Eur Urol. 2017 Apr;71(4):680-687
pubmed: 27733296
Clin Cancer Res. 2017 Aug 15;23(16):4704-4715
pubmed: 28473535
Eur Urol. 2017 Nov;72(5):828-834
pubmed: 28818355
Oncotarget. 2016 Apr 26;7(17):24677-87
pubmed: 27013581
N Engl J Med. 2014 Sep 11;371(11):1028-38
pubmed: 25184630
J Mol Diagn. 2017 Jan;19(1):115-125
pubmed: 27916435
Cell. 2015 Nov 5;163(4):1011-25
pubmed: 26544944
Int J Mol Sci. 2016 Aug 04;17(8):
pubmed: 27527157
PLoS One. 2015 Mar 23;10(3):e0122763
pubmed: 25799582
Cancers (Basel). 2020 Jul 17;12(7):
pubmed: 32708837
Anal Bioanal Chem. 2014 Jan;406(3):661-7
pubmed: 24276251
Cancer Discov. 2018 Mar;8(3):288-303
pubmed: 29301747
Eur Urol. 2014 Feb;65(2):289-99
pubmed: 23957948
Oncotarget. 2015 Apr 23;10(41):4213-4223
pubmed: 31289619
Nat Rev Cancer. 2001 Oct;1(1):34-45
pubmed: 11900250
J Urol. 2017 Jan;197(1):135-142
pubmed: 27436429

Auteurs

Ada Gjyrezi (A)

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.

Giuseppe Galletti (G)

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.

Jiaren Zhang (J)

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.

Daniel Worroll (D)

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.

Michael Sigouros (M)

Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.

Seaho Kim (S)

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.

Victoria Cooley (V)

Department of Population Health Sciences, Division of Biostatistics, Weill Cornell Medicine, New York, NY, USA.

Karla V Ballman (KV)

Department of Population Health Sciences, Division of Biostatistics, Weill Cornell Medicine, New York, NY, USA.

Allyson J Ocean (AJ)

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.

Manish A Shah (MA)

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.

Joseph M Scandura (JM)

Richard T. Silver, M.D. Myeloproliferative Neoplasms Center, Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.

Andrea Sboner (A)

Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA.

David M Nanus (DM)

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.

Himisha Beltran (H)

Dana-Farber Cancer Institute, Boston, MA, USA.

Scott Tagawa (S)

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.

Paraskevi Giannakakou (P)

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA. pag2015@med.cornell.edu.
Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA. pag2015@med.cornell.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH